glp-1 alzheimer's study Glucagon like peptide-1 (GLP-1) likes disease Details of failed studies cast

Tables 2

High dropout rates in obesity and diabetes trials highlight tolerability issues, which may be further compounded in psychiatric populations where comorbid anxiety, cognitive impairment, or poor illness insight can interfere with consistent medication use

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat

GLP-1 Receptor Agonists: The Foundation of Modern Weight Loss Medications GLP-1 receptor agonists are synthetic compounds that mimic the effects of GLP-1 but with much longer half-lives, allowing for daily or even weekly dosing

On the flip side, digital health has the potential to scale low-cost, effective treatments by combining GLP-1 prescribing with tools that promote adherence and drive meaningful behavior change